1. Home
  2. TAOP vs MBAI Comparison

TAOP vs MBAI Comparison

Compare TAOP & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TAOP

Taoping Inc.

N/A

Current Price

$1.30

Market Cap

13.2M

Sector

Technology

ML Signal

N/A

Logo Check-Cap Ltd. Ordinary Share

MBAI

Check-Cap Ltd. Ordinary Share

N/A

Current Price

$1.91

Market Cap

10.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
TAOP
MBAI
Founded
1993
2004
Country
China
Israel
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
13.2M
10.6M
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
TAOP
MBAI
Price
$1.30
$1.91
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
6.8K
58.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.14
$1.31
52 Week High
$8.78
$3.92

Technical Indicators

Market Signals
Indicator
TAOP
MBAI
Relative Strength Index (RSI) 41.61 55.83
Support Level $1.21 $1.38
Resistance Level $1.59 $3.92
Average True Range (ATR) 0.09 0.17
MACD 0.00 0.03
Stochastic Oscillator 19.44 87.74

Price Performance

Historical Comparison
TAOP
MBAI

About TAOP Taoping Inc.

Taoping Inc is a provider of cloud-app technologies for smart city IoT platforms, digital advertising delivery, and other internet-based information distribution systems in China. Its operating segment includes Cloud-based Technology (CBT), Blockchain Technology (BT), and Traditional Information Technology (TIT). It generates maximum revenue from the CBT segment. CBT segment includes cloud-based products and services offered to customers in the private sector including new media, healthcare, education, and residential community management.

About MBAI Check-Cap Ltd. Ordinary Share

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

Share on Social Networks: